| Primary |
| Pain |
35.0% |
| Anxiety Disorder |
20.0% |
| Drug Use For Unknown Indication |
20.0% |
| Tuberculosis |
10.0% |
| Non-small Cell Lung Cancer |
5.0% |
| Plasmacytoma |
5.0% |
| Product Used For Unknown Indication |
5.0% |
|
| Musculoskeletal Pain |
28.6% |
| Encephalopathy |
14.3% |
| Hallucination, Visual |
14.3% |
| Overdose |
14.3% |
| Sepsis |
14.3% |
| Somnolence |
14.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
19.7% |
| Pain |
16.4% |
| Lung Neoplasm Malignant |
8.2% |
| Non-small Cell Lung Cancer |
8.2% |
| Product Used For Unknown Indication |
8.2% |
| Symphysiolysis |
6.6% |
| Analgesic Therapy |
4.9% |
| Hypertension |
3.3% |
| Metastatic Renal Cell Carcinoma |
3.3% |
| Neuralgia |
3.3% |
| Plasmacytoma |
3.3% |
| Antibiotic Therapy |
1.6% |
| Breast Cancer Metastatic |
1.6% |
| Cancer Pain |
1.6% |
| Depression |
1.6% |
| Diuretic Therapy |
1.6% |
| Hypothyroidism |
1.6% |
| Pain Management |
1.6% |
| Pneumonia |
1.6% |
| Prostate Cancer |
1.6% |
|
| Overdose |
20.7% |
| Deep Vein Thrombosis |
10.3% |
| Hallucination |
6.9% |
| Peritonitis |
6.9% |
| Pneumonia |
6.9% |
| Dehydration |
3.4% |
| Drug Exposure During Pregnancy |
3.4% |
| Hepatitis Fulminant |
3.4% |
| Large Intestine Perforation |
3.4% |
| Lower Respiratory Tract Infection |
3.4% |
| Maternal Drugs Affecting Foetus |
3.4% |
| Osteonecrosis |
3.4% |
| Prothrombin Time Prolonged |
3.4% |
| Pulmonary Embolism |
3.4% |
| Respiratory Depression |
3.4% |
| Sepsis |
3.4% |
| Suicidal Ideation |
3.4% |
| Suicide Attempt |
3.4% |
| Toxic Epidermal Necrolysis |
3.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
24.9% |
| Pain |
18.0% |
| Product Used For Unknown Indication |
10.1% |
| Prophylaxis |
8.0% |
| Non-small Cell Lung Cancer |
5.3% |
| Constipation |
5.1% |
| Nausea |
4.6% |
| Analgesic Therapy |
4.2% |
| Rheumatoid Arthritis |
2.8% |
| Hypertension |
2.7% |
| Prostate Cancer |
2.3% |
| Breast Cancer |
1.6% |
| Breast Cancer Metastatic |
1.4% |
| Neuralgia |
1.4% |
| Plasmacytoma |
1.4% |
| Renal Cell Carcinoma |
1.4% |
| Hiv Infection |
1.3% |
| Dyspepsia |
1.2% |
| Dyspnoea |
1.1% |
| Insomnia |
1.1% |
|
| Vomiting |
12.5% |
| Sepsis |
11.8% |
| Neutropenic Sepsis |
6.9% |
| Renal Failure Acute |
6.3% |
| Pyrexia |
5.6% |
| Renal Failure |
5.6% |
| Respiratory Failure |
5.6% |
| Thrombocytopenia |
4.9% |
| Death |
4.2% |
| Dyspnoea |
4.2% |
| Pulmonary Embolism |
4.2% |
| General Physical Health Deterioration |
3.5% |
| Neutropenia |
3.5% |
| Osteonecrosis |
3.5% |
| Septic Shock |
3.5% |
| Vascular Skin Disorder |
3.5% |
| Diarrhoea |
2.8% |
| Nausea |
2.8% |
| Overdose |
2.8% |
| Pericardial Effusion |
2.8% |
|
| Interacting |
| Pain |
33.3% |
| Avoidant Personality Disorder |
19.0% |
| Depression |
19.0% |
| Tuberculosis |
14.3% |
| Personality Disorder |
9.5% |
| Neuralgia |
4.8% |
|
| Sleep Disorder |
50.0% |
| Therapeutic Product Ineffective |
25.0% |
| Musculoskeletal Pain |
12.5% |
| Transient Ischaemic Attack |
12.5% |
|
